Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme

Journal of Neuro-Oncology, 03/05/2012

Urgoiti GBR et al. – The data suggest extended adjuvant temozolomide (i.e., more than six cycles) should be considered in patients with newly diagnosed glioblastoma multiforme (GBM).


  • The authors conducted a population-based analysis to determine if extended adjuvant TMZ treatment (i.e., more than six cycles) confers a survival advantage as compared to the standard six cycles for newly diagnosed GBM patients.
  • Patient data was collected from the Alberta Cancer Registry and patient charts.
  • Progression free-and overall survival was determined in patients receiving six cycles of adjuvant TMZ and compared with that of patients receiving more than six cycles.


  • Patients in whom adjuvant chemotherapy was stopped at cycle six experienced a median survival of 16.5months, whereas, those who received more than six cycles survived for 24.6months (p=0.031).
  • Extended adjuvant therapy was not associated with increased toxicity.
  • In multivariate analysis, adjuvant monthly Temozolomide for more than six cycles was an independent prognostic factor for both progression free-and overall survival.

Print Article Summary Cat 2 CME Report